In conclusion, Nomogram which integrates DLRadiomics, Pathomics and clinical features, can serve as a non-invasive biomarker for predicting EGFR mutation status and risk stratification in NSCLC patients and guiding clinical treatment decisions. This evidence concerns the gene EGFR and non-small cell lung carcinoma.